Aspen Pharmacare Holdings Limited · JSE:APN
Aspen Pharmacare — H1 2018 Earnings Presentation
76 slides from Aspen Pharmacare's earnings presentation, Mar 8, 2018
Slide 1: Interim Results Presentation
Interim Results Presentation For the six months ended 31 December 2017
Slide 2: Table of Contents
TABLE OF CONTENTS Stephen Saad Group Chief Executive Aspen’s 20 Year History Unpacking Aspen H1 2018 Performance Review Gus Attridge Deputy Group Chief Executive Financial Review Stephen Saad Summary & Prospects Appendices
Slide 3: Financial Highlights
FINANCIAL HIGHLIGHTS 3 Strong H1 performance Revenue at ZAR 21.9bn − Revenue momentum sustained from H2 2017 EBITDA at ZAR 6.3bn − EBITDA growth above revenue growth − Operating profit to cash flow conversion rate 78% Forecast at 100% for the year Growth CER Growth NHEPS (cents) vs prior yea
Slide 4: Group Revenue
GROUP REVENUE 4 R’million H1 2018 H1 2017 % change H1 2017 (CER)* % change Commercial Pharma 17 121 14 997 14% 14 893 15% Anaesthetics 4 409 2 817 57% 2 766 59% Thrombosis 3 276 2 729 20% 2 793 17% High Potency & Cytotoxics 2 193 2 417 -9% 2 383 -8% Regional Brands 7 243 7 035 3% 6 951 4% Nutritiona
Slide 5: Aspen's 20-year history
Hot DING Ss Aspen’s 20-year history
Slide 6: Celebrating 20 Years | 1999 - 2018
CELEBRATING 20 YEARS | 1999 - 2018 6 FY1999 – FY2013 FY2014 – H1 2018 (annualised) From humble beginnings to regional leadership From regional leadership to global therapeutic leadership annualised Going for 20th year of unbroken NHEPS growth
Slide 7: FY 1999 – FY 2013
FY 1999 – FY 2013 7 FY 1999 Sales: ZAR 0.5bn FY 2013 Sales: ZAR 19.3bn SA & Australia = 73% Rest of World • No 1 in SA ~ 1 in 4 scripts 27% South Africa dispensed 36% • No 1 in Australia ~ 1 in 5 scripts written Australasia 37% South Africa only From humble beginnings in Durban to regional leadershi
Slide 8: Regional Learning Defines Global Strategy
REGIONAL LEARNING DEFINES GLOBAL STRATEGY 8 Strategic review of our strengths & weaknesses in 2013 Returns from scale, sales and supply chain − Risk of commoditisation of generics − Critical mass gives returns − Funding required for patents − Global strategy formulated − Fifteen years taken to b
Slide 9: FY 2013 – H1 2018 (Annualised)
FY 2013 – H1 2018 (ANNUALISED) 9 FY 2013 Sales: ZAR 19.3bn H1 2018 (annualised) Sales : ZAR 43.8bn SA & Australia = 73% SA & Australia = 35%* South Africa Rest of • No.1 in Anaesthetics globally (ex-USA) 20% World South Africa • No.2 in injectable Anticoagulants 27% 36% globally (ex-USA) Australasia
Slide 10: Unpacking Aspen
Unpacking Aspen FY 2013 – H1 2018
Slide 11: Debt & Assets
DEBT & ASSETS 11 Debt − Net borrowings ↑ ZAR 32.0bn since FY 2013 67.3 Assets − Significant increase in balance sheet values Intangibles ↑ ZAR 48.4bn 43.1 PPE ↑ ZAR 5.8bn Applied to Working Capital ↑ ZAR 12.4bn 18.9 17.8 11.1 5.4 FY 2013 H1 2018 Net borrowings (ZAR'bn) Intangible Assets (Z
Slide 12: Intangible Assets & Goodwill
INTANGIBLE ASSETS & GOODWILL 12 High Potency & Regional Brands Therapeutic class Anaesthetics Thrombosis Other Cytotoxic South Africa Australia Sales Multiple 2.6 2.1 2.8 0.4 1.9 0.9 23.0 14.0 14.6 13.0 12.1 8.8 6.6 6.9 4.4 5.8 3.6 2.1 Anaesthetics Thrombosis High Potency and South Africa - Australi
Slide 13: Amortisation of Intangibles
AMORTISATION OF INTANGIBLES 13 Amortisation treatment differs between generics, Useful life assessed against, inter alia patents and brands − Historic & budgeted sales − Aspen has mainly indefinite life intangibles − Investment plans & willingness to commit resources Means the values are teste
Slide 14: Investment in Capex & Working Capital
INVESTMENT IN CAPEX & WORKING CAPITAL 14 Capex investments critical − Security of supply − Global advantage Economies of scale Lower COGS, higher quality Sustainability of entire business model Capex projects are long term All capex approved with a commercial return Working Capital +ZA
Slide 15: Quality of Earnings
QUALITY OF EARNINGS 15 We validate quality of earnings by comparing Operating cash flow per share vs Operating income per share We have a successful 20 year history on this metric Cash is King − Cuts through all accounting nuances Cash then applied to − Capex, acquisitions & dividends We h
Slide 16: Our Current GPS
OUR CURRENT GPS 16 Aspen has globalised Leading global and regional positions Substantial acquisitions have been settled − No 1 in anaesthetics (excluding USA) Enhanced capability and capacity − No 2 in injectable anticoagulants (excluding USA) − Globally valuable IP − Differentiated and com
Slide 17: Our Current GPS (Continued)
OUR CURRENT GPS (CONTINUED) 17 Over the last 12 months Acquisitions in pharma are expensive − ↑ Margins − Acquisitive only financiers in pharma and other industries have often failed − ↑ EBITDA > ↑ Sales In spite of heavy equity funding Accelerating EBITDA margin Aspen has also grown inorg
Slide 18: What Is the Bottom Line? FY 2013 – H1 2018
WHAT IS THE BOTTOM LINE? | FY 2013 – H1 2018 (ANNUALISED) 18 Aspen has not only diversified into a global multinational − More than doubled revenue − Without diluting EBITDA margins Extent of the successful metamorphosis is best measured by Operating profit +105% NHEPS +108% New shares issued NI
Slide 19: H1 2018 Performance Review
Hot DING Ss H1 2018 Performance Review
Slide 20: Commercial Pharma Revenue Contribution by Region & Therapeutic Category
COMMERCIAL PHARMA REVENUE CONTRIBUTION | BY REGION & THERAPEUTIC CATEGORY 20 Total Commercial Pharma Revenue +15% ZAR17.1 bn 54% -27% EM revenue Latam ROW contribution +6% ZAR 1.0bn +59% Developing +22% Europe & CIS 6% Asia Pacific Anaesthetics SSA Emerging ZAR 2.3bn Markets 13% ZAR 4.4bn China 26%
Slide 21: Anaesthetic Brands
ANAESTHETIC BRANDS 21 Regional representation R’million H1 2018 H1 2017 % change (CER) 46% Developed Markets 2 374 1 561 52% Latam EM revenue China Contribution Emerging Markets 2 035 1 205 69% +69% Emerging Total Revenue 4 409 2 766 59% Markets Largest area of focused brands MENA North − Base eff
Slide 22: Anaesthetic Brands
ANAESTHETIC BRANDS 22 China’s return to growth sustained − Diprivan +7% vs -19.7% in Dec 2015 − Naropin +1% in Dec 2015 +20% before supply impact -23% after supply impact Brazil overperforming in Latam Future sustainable supply through Aspen sites − Well positioned to compete globally Gl
Slide 23: Thrombosis Brands
THROMBOSIS BRANDS 23 R’million H1 2018 H1 2017 % change Regional representation (CER) Developing 44% Developed Markets 1 841 1 675 10% Europe & CIS EM revenue Emerging Markets 1 435 1 118 28% Contribution +28% Total Revenue 3 276 2 793 17% Emerging China Markets Developed EU +11% MENA, Latam& SSA
Slide 24: High Potency & Cytotoxic Brands
HIGH POTENCY & CYTOTOXIC BRANDS 24 R’million H1 2018 H1 2017 % change Regional representation (CER) Developed Markets 1 294 1 459 -11% Developing 41% Latam Europe & CIS EM revenue Emerging Markets 899 924 -3% contribution Total Revenue 2 193 2 383 -8% Emerging -3% Markets Asia North Decline exclus
Slide 25: Regional Brands
REGIONAL BRANDS 25 Regional representation R’million H1 2018 H1 2017 % change (CER) SSA 67% SSA 3 868 3 298 17% EM revenue Asia Pacific 2 293 2 170 6% contribution +13% Latam 614 590 4% Emerging Rest of World 468 893 -48% Markets Total Revenue 7 243 6 951 4% Excluding HPC, category grew +10% − Imp
Slide 26: Regional Brands | SSA
REGIONAL BRANDS | SSA 26 R’million H1 2018 H1 2017 % change Private Sector +14% − Aspen has largest share in Private Sector Total SA Revenue 3 480 2 870 21% No 1 brand 4 of the top 10 brands Private sector 2 500 2 186 14% 5 of the top 15 generics - OTC 827 598 38% Prescription +5% - Prescr
Slide 27: Regional Brands | Asia Pacific
REGIONAL BRANDS | ASIA PACIFIC 27 R’million H1 2018 H1 2017 % change (CER) Total Australasia Revenue 1 958 1 912 2% OTC 443 413 7% Prescription 1 515 1 499 1% Total Asia Revenue 335 258 30% Total Asia Pacific Revenue 2 293 2 170 6% Australasia ̶ OTC +7% Robust performance of new molecules launch
Slide 28: Commercial Pharma | Prospects
COMMERCIAL PHARMA | PROSPECTS 28 Anaesthetics synergistic Operational performance areas to include − Fit for existing infrastructures − Focus Brands − Consistent global supply Anaesthetics - supply management Strategic advantage Thrombosis - maintain current momentum Complexity of manufa
Slide 29: Nutritionals
NUTRITIONALS 29 R’million H1 2018 H1 2017 % change (CER) Latin America 658 704 -7% SSA 497 490 1% Asia Pacific 455 428 6% Total Revenue 1 610 1 622 -1% Latam Asia Pacific − Positive growth in Infacare in Mexico medium-price segment − Market now stabilised Offset by “Breastfeeding is Best” camp
Slide 30: Operations
OPERATIONS 30 R’million H1 2018 H1 2017 % change (CER) API 2 297 2 164 6% FDF 896 1 072 -16% Total Revenue 3 193 3 236 -1% Strong API performance continues Manufacturing facilities being reshaped − Both FCC & Oss − Oss end-state by June 2018 − Demonstration of capability FDF affected by − Prou
Slide 31: Financial review
Hot DING Ss Financial review
Slide 32: Financial Performance Headlines
FINANCIAL PERFORMANCE HEADLINES 32 Acquisitive and organic Improved margin % Lower revenue growth Finance charges Benefit of second transaction Currency influence: Capex spend realignment with Astra Zeneca neutral below plan Working capital Cash Flows Leverage ratio stable on track comfortable
Slide 33: Abridged Statement of Normalised Comprehensive Income
ABRIDGED STATEMENT OF NORMALISED COMPREHENSIVE INCOME 33 R ’million H1 2018 H1 2017 % change H1 2017 % change (CER) Net revenue 21 924 19 822 11% 19 751 11% Cost of sales (10 747) (10 259) 5% (10 131) 6% Gross profit 11 177 9 563 17% 9 620 16% Gross profit margin 51% 48% 49% EBITDA 6 306 5 499 15% 5
Slide 34: Currency Impact | H1 2018
CURRENCY IMPACT | H1 2018 34 26% Revenue 23% 20% Reported CER 14% Revenue +11% +11% 7% Normalised EBITDA +15% +13% 5% 5% NHEPS +26% +25% EUR ZAR AUD USD JPY CNY Other Most relevant currencies affecting earnings − EUR, ZAR, AUD − CNY, JPY − USD Maintenance of stronger ZAR will be unfavourable to
Slide 35: EBITDA Margin
EBITDA MARGIN 35 Contribution to change in Normalised EBITDA Margin +1.1% -2.9% -1.4% -0.2% 5.9% -1.4% -1.0% -0.3% -0.4% 28.8% 27.7% Gross profit +2.8% -0.9% Net opex -1.7% H1 2017 Therapeutic Regional Brands Nutritionals Selling & Administrative Net other H1 2018 Normalised focused brands Distribut
Slide 36: Reconciliation of NHEPS
RECONCILIATION OF NHEPS 36 Cents H1 2018 H1 2017 % change Basic earnings per share (EPS) 806.0 618.6 30% Profit on sale of property, plant and equipment 0.2 0.5 -64% Net impairment of property, plant and equipment 2.5 0.3 >100% Impairment of intangible assets 33.1 8.5 >100% Loss on sale of intangibl
Slide 37: Net Funding Costs
NET FUNDING COSTS 37 R’million H1 2018 H1 2017 % change Net interest paid (734) (771) -5% Foreign exchange gains /(losses) 140 (52) > 100% Forward exchange contracts losses (90) (101) -11% Notional interest on financial instruments (136) (155) -12% Normalised net funding costs (820) (1,079) -24% Deb
Slide 38: Intangible Assets
INTANGIBLE ASSETS 38 R’million H1 2018 FY 2017 Net book value 67 326 60 006 Indefinite period useful life intangible assets first recognised in FY 2009 – after initial global brands acquisition − Accounting treatment very similar to goodwill Per IAS 38, an indefinite period useful life intangibl
Slide 39: Intangible Assets | Product Life Cycle
INTANGIBLE ASSETS | PRODUCT LIFE CYCLE 39 Patent-protected Post- patent expiry SALES VALUE ASPEN ACQUIRES LAUNCH YEARS
Slide 40: Intangible Assets (Continued)
INTANGIBLE ASSETS (CONTINUED) 40 Aspen’s business model is based upon building a product portfolio generating sustainable, predictable cash flows − Not patent protection dependant − Not a first-to-launch generic play Approximately ZAR 2.5bn in profits has been realised on the sales of businesses
Slide 41: Intangible Assets (Continued)
INTANGIBLE ASSETS (CONTINUED) 41 Contextualisation of indefinite period useful life recognition − Compliant with International Accounting Standards − FY 2018 is the tenth year of continuous application by Aspen − Rigorous annual impairment testing is performed − Does not result in over-valuation o
Slide 42: Effective Tax Rate
EFFECTIVE TAX RATE 42 H1 2018 H1 2017 FY 2017 Aspen’s effective tax rate is the product of the mix of underlying tax rates of countries in which the Group generates Unadjusted 18.1% 18.1% 18.0% its income − Mix is variable, influenced by performance and evolution of Normalised 17.6% 16.8% 17.1% pr
Slide 43: Effective Tax Rate (Continued)
EFFECTIVE TAX RATE (CONTINUED) 43 Aspen does not pursue aggressive tax structures − No off-balance sheet financing − No trusts and similar look-through structures Aspen seeks to be fully compliant with OECD transfer pricing principles and in-country tax legislation − Allocation of earnings throu
Slide 44: PPE Capital Expenditure
PPE CAPITAL EXPENDITURE 44 Major projects underway to enable Aspen to manufacture Anaesthetics PPE Capex - ZAR'million − Port Elizabeth - steriles 2 500 2 400 − Notre Dame de Bondeville – blow-fill seal 2 000 H2 − Bad Oldesloe – creams, gels, liquids 1 580 1 500 1 000 1 593 1 741 1 329 1 484 500 8
Slide 45: Cash Flows
CASH FLOWS 45 R’million H1 2018 H1 2017 Operating Cash Flow - R’million H1 2018 Net Working capital 17 793 16 635 Net Working capital – excluding Oss 13 413 12 375 Working capital as % of revenue 41% 42% 6 145 -1 013 -607 -1 523 Less: Attributable to Oss -7% -8% 3 002 Working capital excluding Oss a
Slide 46: Borrowings
BORROWINGS 46 R’million H1 2018 H1 2017 Blended interest rates for borrowings Opening balance 37 131 32 694 Debt denomination H1 2018 Weighted average rate p.a (NACQ) Cash flow from operating activities (3 002) (3 232) as at 31 December 2017 Capital expenditure 820 736 ZAR 8.60% AUD 3.82% Proceeds f
Slide 47: Borrowings
BORROWINGS 47 Net Debt: R43.1 billion Analysis of ZAR43.1 billion net borrowings 35.6 Net borrowings 43.1 South Africa 9.5 Cash ZAR 8.5 22% H1 2017 Asia Pacific 9.4 H1 2018 AUD Current 22.0 5% International EUR 35.6 Non-current 73% 29.6 0.0 10.0 20.0 30.0 40.0 50.0 Amend and extend exercise planne
Slide 48: Summary & prospects
Hot DING Ss Summary & prospects
Slide 49: Pipeline
PIPELINE 49 Pipeline – Focus Brands − Thrombosis – geographic expansion of Orgaran − Anaesthetics Additional European territories submitted existing products USA reactivation submission June 2018 Enabled by lower COGS Clinical trials for HIT indication existing products, new markets
Slide 50: Synergies
SYNERGIES 50 Key operational synergies include, inter alia − Capacity reshape and volume growth in NDB facility − Bringing Mono-Embolex into Aspen supply chain − Restructuring Oss facilities and outsourcing intermediates − Fixing Danaparoid and Estrogens Commercial synergies could include HPC
Slide 51: Nutritionals | Globally
NUTRITIONALS | GLOBALLY 51 We are reviewing our strategic options for infant formula Aspen has a strong market position in key geographies − Asia Pacific: No 2 in Australia − South Africa: No 2 in SA − Latam: Top 4/5 in most markets Key growth opportunities − Registration in China Estimated
Slide 52: Nutritionals | China Strategy
NUTRITIONALS | CHINA STRATEGY 52 Registration in January 2018 E-commerce − Ahead of March date − 18.3% market share ±2000 brands currently − Highest growth rate +19% − Could fall to 500 − JD.com, Taobao, DanDan and Amazon Focus on two routes-to-consumer Expanding to Sunning and others − E-
Slide 53: Regulatory Challenges
REGULATORY CHALLENGES 53 Addressed major EHS challenges at Oss − Real threat of closure Environmental – remediation project agreed − All leakage repaired Health & Safety – addressed fire, hazardous materials and personal protection − Resolved through safe storage locations − Process and rebuil
Slide 54: Commercial Pharma | Geographic Overview
COMMERCIAL PHARMA | GEOGRAPHIC OVERVIEW 54 Asia Pacific Europe CIS − Asia Pacific now 33% of total Commercial Pharma revenue − Sustain momentum change in Thrombosis momentum − 3 of top 5 sales countries are in Asia Pacific region Latam − Asia > Australia − Brazil settled and performing 4 yea
Slide 55: Commercial Pharma | Growth Highlights
COMMERCIAL PHARMA | GROWTH HIGHLIGHTS 55 Total Commercial Pharma +15% DM +7% EM +22% Focus Brands +24% DM +17% EM +35% Focus Brands +6% DM +0% EM +14% excl. Anaesthetics Regional Brands +4% DM -11% EM +13% Regional Brands excl. HPC +10% DM +5% EM +13%
Slide 56: Commercial Pharma | Internal Organic Sales Growth Measure
COMMERCIAL PHARMA | INTERNAL ORGANIC SALES GROWTH MEASURE 56 Total Commercial Pharma +15.0% Adjusted for: Anaesthetics -7.9% Thrombosis in China Divestments HPC in USA Base Organic Growth +7.1%
Slide 57: Our Business Model
OUR BUSINESS MODEL 57 20th year of unbroken NHEPS growth at half year − Intention to sustain into H2 2018 Aspen has settled acquisitions made − Transformative period with focus on organic synergies Grow established brands − Investment − Optimise supply chain − Line extensions/delivery forms −
Slide 58: Our Business Model (Continued)
OUR BUSINESS MODEL (CONTINUED) 58 Aspen has a simple commercial business model − Albeit operationally complex Providing quality medicine − Affordably − Sustainability assured Relevant and resilient to future healthcare pressures − Strong cash flow De-risked relative to multinational and gene
Slide 59: Prospects for H2 2018
PROSPECTS FOR H2 2018 59 Sales performance Anaesthetics supply constraints − Target H2 ≥ H1 in CER Currency − Both Focus & Regional Brands VS ZAR EURO* USD** Improved margins maintained H2 2017 14.43 13.28 Cash flow stronger in H2 2018 H1 2018 15.77 13.41 − Targeting 100% conversion for fu
Slide 60: Our Purpose
OUR PURPOSE 60 Aspen has a real purpose − Touch patients’ lives globally Every second of every day 24 hours a day 365 days a year To patients in need across the globe We provide over − 12 anaesthetics/sterile products; and − 500 tablets/capsules Life is like a bicycle This is our real
Slide 61: Thank you
© aspen Thank you
Slide 62: Disclaimers
DISCLAIMERS 62 BASIS OF PREPARATION – ROUNDING OF NUMBERS The financial results in this presentation have been rounded and disclosed in R‘millions whereas the published unaudited interim financial results have been rounded and disclosed in R ’billions. Consequently there may be rounding differences
Slide 63: Appendices
Hot DING Ss Appendices
Slide 64: Appendices
APPENDICES 64 Appendix 1: Abridged Group statement of comprehensive income Appendix 2: Group statement of financial position Appendix 3: Extract from Group statement of cash flows Appendix 4: Key currency movements vs ZAR - H1 2018 vs H1 2017 Appendix 5: Institutional investors Appendix 6: Group rev
Slide 65: Appendix 1: Abridged Group Statement of Comprehensive Income
APPENDIX 1: ABRIDGED GROUP STATEMENT OF COMPREHENSIVE INCOME 65 R’million H1 2018 H1 2017 % change Net revenue 21,924 19,822 11% Cost of Sales (10 747) (10 259) 5% Gross profit 11 178 9 563 17% Gross profit margin 51% 48% Net other operating expenses (339) (106) 221% Net operating expenses (5 674) (
Slide 66: Appendix 2: Group Statement of Financial Position
APPENDIX 2: GROUP STATEMENT OF FINANCIAL POSITION 66 R'million H1 2018 H1 2017 TOTAL ASSETS Non-current assets 86 351 71 814 Intangible assets 67 326 53 610 Property, plant and equipment 10 105 9 654 Goodwill 6 003 5 716 Deferred tax assets 1 017 1 042 Contingent environmental indemnification assets
Slide 67: Appendix 2: Group Statement of Financial Position (Continued)
APPENDIX 2: GROUP STATEMENT OF FINANCIAL POSITION (CONTINUED) 67 R‘million H1 2018 H1 2017 EQUITY AND LIABILIITIES Share capital and reserves 44 337 39 590 Non-current liabilities 37 811 44 003 Borrowings 29 579 35 585 Other non-current liabilities 2 984 3 334 Unfavourable and onerous contracts 1 47
Slide 68: Appendix 3: Extract from Group Statement of Cash Flows
APPENDIX 3: EXTRACT FROM GROUP STATEMENT OF CASH FLOWS 68 R'million H1 2018 H1 2017 Cash operating profit 6 145 5 496 Changes in working capital (1 523) (691) Cash generated from operations 4 622 4 805 Net finance costs paid (607) (915) Tax paid (1 013) (658) Cash generated from operating activities
Slide 69: Appendix 4: Key Currency Movements vs ZAR
APPENDIX 4: KEY CURRENCY MOVEMENTS VS ZAR – H1 2018 VS H1 2017 69 17.67 GBP 17.75 0% 15.77 EUR 15.25 +3% 13.41 USD 13.94 -4% 10.45 AUD 10.46 0% 4.15 BRL 4.27 -3% 3.71 PLN 3.5 +6% 2.02 CNY 2.06 -2% H1 2018 Average rate 0.72 MXN 0.72 +1% H1 2017 Average rate 0.23 RUB 0.22 +5% 0.12 JPY 0.13 -8%
Slide 70: Appendix 5: Institutional Investors
APPENDIX 5: INSTITUTIONAL INVESTORS 70 Asia Pacific ROW 4% 5% Europe 3% UK 6% North America 18% South Africa 64% As at 29 December 2017
Slide 71: Appendix 6: Group Revenue by Region
APPENDIX 6: GROUP REVENUE BY REGION 71 R’million H1 2018 H1 2017 % change H1 2017 % change (CER)* Developed Europe 6 295 5 592 13% 5 763 9% Asia Pacific 6 297 5 237 20% 5 088 24% Sub Saharan Africa 5 030 4 602 9% 4 570 10% Latin America 2 179 1 945 12% 1 925 13% Developing Europe and CIS 1 413 1 153
Slide 72: Appendix 7: Merck & Co
APPENDIX 7: MERCK & CO 72 Source: Merck Full year and fourth quarter 2017 results press release
Slide 73: Appendix 7: Mylan
APPENDIX 7: MYLAN 73 Source: Mylan Full year and fourth quarter 2017 results presentation
Slide 74: Appendix 7: Hikma
APPENDIX 7: HIKMA 74 Source: Hikma H1 2017 results press release
Slide 75: Appendix 7: Allergan
APPENDIX 7: ALLERGAN 75 Source: Allergan Full year and fourth quarter 2017 results presentation
Slide 76: Appendix 7: GSK
APPENDIX 7: GSK 76 Source: GSK Full year and fourth quarter 2017 results press release
Aspen Pharmacare Holdings — H1 2018 Earnings Presentation on 6ix